

Serial No. 09/502,176

Title: *Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*

Amendment and Response to Office Action

Filed: February 10, 2000

Page 2

RECEIVED
CENTRAL FAX CENTER
JUL 07 2006

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment lacks one or ~~more~~ two carbohydrate moieties found in moieties linked to naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the deglycosylated kringle 1-3 region fragment and a glycosylated form of the fragment are at a ratio of 100:0.
2. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.
3. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.
4. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at an amino acid position corresponding to an N-glycosylation site of human plasminogen.
5. (Cancelled)
6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.
6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use

Amendment and Response to Office Action

Filed: February 10, 2000

Page 3

7 8. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

8 9. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10-14. (Cancelled)

9 15. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

10 16. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

17-26 (Cancelled)

11 27. (Previously Presented) A deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

28. (Cancelled)

20 29. (Previously Presented) The composition of claim 40, wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition.

30-34. (Cancelled)

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use

Amendment and Response to Office Action

Filed: February 10, 2000

Page 4

16 35. (Previously Presented) The composition of claim 39, wherein the
deglycosylated kringle 1-3 region fragment is produced recombinantly. 15

36. (Cancelled)

17 37. (Previously Presented) The composition of claim 39, wherein the
deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*. 15

18 38. (Previously Presented) The composition of claim 39, wherein the
deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*. 15

15 39. (Previously Presented) A composition comprising a pharmaceutically
acceptable carrier and a protein consisting of a deglycosylated kringle 1-3 region fragment of
a plasminogen protein wherein the deglycosylated kringle 1-3 region fragment lacks one or
more carbohydrate moieties linked to naturally glycosylated forms of the fragment, wherein
the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the
deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

19 40. (Previously Presented) The composition of claim 39, further
comprising a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a
plasminogen protein. 15

12 41. (Currently Amended) The deglycosylated kringle 1-3 region fragment
composition of claim 21, wherein the deglycosylated kringle 1-3 region fragment is produced
recombinantly.

Serial No. 09/502,176

Title: *Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*

Amendment and Response to Office Action

Filed: February 10, 2000

Page 5

13 42. (Currently Amended) The deglycosylated kringle 1-3 region fragment
composition of claim 27, wherein the deglycosylated kringle 1-3 region fragment has
antiangiogenic activity *in vitro*.

14 43. (Currently Amended) The deglycosylated kringle 1-3 region fragment
composition of claim 27, wherein the deglycosylated kringle 1-3 region fragment has
antiangiogenic activity *in vivo*.